<DOC>
	<DOCNO>NCT02423096</DOCNO>
	<brief_summary>Background : Schizophrenia serious mental illness . The diagnosis severity evaluation schizophrenia generally base patient behavior . Biomarkers objectively measure used indicator diagnosis confirmation , symptom assessment , evaluation pharmacologic responses therapeutic intervention . Neuroendocrine metabolite substrate potential biomarkers pathogenic process schizophrenia . Aims : The aim study determine ( ) differences neuroendocrine metabolite substrate patient diagnose schizophrenia healthy control ; ( b ) association among neuroendocrine metabolite substrate , cognitive function , clinical symptom , treatment response patient diagnose schizophrenia . Methods : ( ) The investigator plan recruit 100 patient diagnose schizophrenia 100 healthy control participant . ( b ) At baseline Week 12 , patient blood sample obtain measure level neuroendocrine substrates metabolite marker . Clinical symptom cognitive function evaluate . ( c ) For healthy control participant , blood sample obtain measure neuroendocrine metabolite marker level . Expected Results : The result study may contribute identify potential neuroendocrine metabolite biomarkers schizophrenia , clarify association among neuroendocrine metabolite substrate , cognitive function , clinical symptom , treatment response patient diagnose schizophrenia . Such information crucial clinical evaluation future research .</brief_summary>
	<brief_title>Neuroendocrine Metabolite Substrates Schizophrenia</brief_title>
	<detailed_description>1 . The investigator plan recruit 100 patient schizophrenia 100 healthy control subject . 2 . For patient , diagnose schizophrenia confirm use Chinese version Mini International Neuropsychiatric Interview ( MINI ) . At baseline Week 12 , patient blood sample obtain measure level neuroendocrine substrate ( didehydroepiandrosterone , dehydroepiandrosterone sulfate , pregnenolone , cortisol ) metabolite marker ( lipid profile , glycerate , eicosenoic acid , pyruvate , b-hydroxybutyrate , Cysteine ) . Cognitive function evaluate use Brief Assessment Cognition Schizophrenia . The participant ' clinical symptom daily activity assess use Positive Negative Syndrome Scale , 17-item Hamilton Depression Rating Scale , Personal Social Performance Scale . 3 . For healthy control subject , psychiatric diagnosis verify use MINI , blood sample obtain measure neuroendocrine metabolite marker level .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Haloperidol</mesh_term>
	<mesh_term>Olanzapine</mesh_term>
	<mesh_term>Haloperidol decanoate</mesh_term>
	<mesh_term>Risperidone</mesh_term>
	<mesh_term>Quetiapine Fumarate</mesh_term>
	<mesh_term>Sulpiride</mesh_term>
	<criteria>Patients Schizophrenia Inclusion criterion : 1 . Diagnosed schizophrenia confirm use Chinese version Mini International Neuropsychiatric Interview ( MINI ) . 2 . Age 18 79 . 3 . Have sign inform consent . Exclusion criterion : 1 . Having history illicit drug use major psychiatric disorder ( e.g. , bipolar disorder , major depressive disorder , organic mental disorder ) . Healthy Controls Inclusion criterion : 1 . Psychiatric diagnosis without schizophrenia confirm use Chinese version MINI . 2 . Age 18 79 . 3 . Have sign inform consent . Exclusion criterion : 1 . Having history illicit drug use major psychiatric disorder ( e.g. , psychosis , bipolar disorder , major depressive disorder , organic mental disorder ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>biomarker</keyword>
	<keyword>neuroendocrine</keyword>
	<keyword>metabolite</keyword>
	<keyword>cognitive functioning</keyword>
	<keyword>clinical symptom</keyword>
	<keyword>schizophrenia</keyword>
</DOC>